

Appn # 08/859,579

11/21/03



Buchert

In the United States Patent and Trademark Office

Appn. Number: 10/604,851  
Filing Date: 08/21/2003  
Applicant: Janusz M. Buchert  
Appn. Title: Thermal Emission Non-Invasive Analyte Monitor  
Art Unit: 3737

RECEIVED

NOV 26 2003

TECHNOLOGY CENTER R3700

November 19, 2003

### Information Disclosure Statement

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Attached is completed Form PTO- 1449 and copies of the pertinent parts of the reference cited thereon (excluding US Patents and Patents Applications). Following are comments on these references pursuant to Rule 98:

**Buchert** [1] shows a method and instrument for the non-invasive detection of an analyte concentration in human body tissue. The Buchert's method and instrument uses **spectral characteristic of the natural infrared body emission** and its characteristics, which include emission of spectral lines characteristic to body fluid analyte and appropriate **changes of monochromatic emissivity** due to concentration changes of tissue analytes.

**Buchert** [2] shows a method and instrument for **continuously determining human body tissue analyte concentration** by non-invasive measurement of the state of spectral emission characteristics of radiation naturally emitted by human tissue in the infrared spectral region, which can be correlated with tissue analyte concentration.

**Fraden** [3] shows an electronic non-contacting infrared thermometer and a method for measuring the temperature of an object using the pyroelectric sensor.

**Kaiser** [4] shows a method and instrument for determining the amounts of metabolic products in blood **using ATR prism and a laser beam**.

**Knudson** [5-7] shows an apparatus and method for a blood constituent measurement by **measuring the intensity of the testing light** while the fluid spectrally modifies the reference light.

**Braig** [8] shows a self-emission non-invasive infrared spectrophotometer for monitoring glucose and other blood constituents. The measurements are made by **monitoring infrared absorption** of the desired blood constituent in the long infrared wavelength range. The long wavelength infrared energy emitted by the person as heat is monitored and the **infrared absorption of particular constituents** in the blood is measured at characteristic infrared absorption wavelengths for the constituents. The measurements are preferably synchronized with the systole and diastole of the cardiac

cycle so that the signal contribution caused by veins and tissues (which do not pulse) may be canceled when a ratio of the detected signal is taken.

**Braig** [9] shows also a method and apparatus where the internal "blackbody" energy level of an infrared emission source such as a vascularized appendage prior to **glucose absorption is measured** and used to compensate temperature dependent effects in the concentration calculation.

**Sterling** [10-12] shows spectrometric methodology and noninvasive **infrared absorption spectrometer** for non-invasively obtaining optical spectra by transient or steady state subsurface **thermal gradient methodology**. The measure infrared energy is processed into **absorption spectra** and then into a concentration of at least one constituent of the body. Embodiments describe the heating and cooling of the heterogenous body to induce and capture the **transient infrared absorption spectral information**.

**Kramer** [13] and **Braig** [15] show a spectrometer for the non-invasive generation and capture of **thermal gradient spectra** from human or animal tissue. The spectrometer includes thermal mass for inducing a **transient temperature gradient** in the tissue by conductive heat transfer with the tissue. Also provided is an infrared sensor for **detecting infrared emissions from the tissue as the transient temperature gradient progresses** into the tissue, and for providing output signals proportional to the detected infrared emissions.

**Braig** [14, 16-18] shows a method and apparatus of determining the analyte concentration of a test sample is described. A **temperature gradient is introduced** in the test sample and infrared radiation detectors measure radiation at selected **analyte absorbance peak** and reference wavelengths. The modulation of the temperature gradient is controlled by a surface temperature modulation. The phase and magnitude differences due to temperature modulation, having a relationship to analyte concentration, are measured, correlated, and processed to determine analyte concentration in the test sample.

**Block** [19] provides non-invasive methods and apparatus for measurement of the concentration of a selected constituent of a subject's blood. The invention cools a segment of the subject's tympanic membrane and employs the thermal radiation that the subject's **inner ear emits and is transmitted (absorbed) through this cold segment** to directly obtain absorption information related to the concentration of various constituents of blood flowing through the membrane.

**Makarewicz** [20] shows a method and apparatus for minimizing variations in spectral measurement caused by fluctuations in tissue state by monitoring a selected tissue state parameter spectroscopically and maintaining the selected parameter within a target range. The invention provides a method and apparatus for minimizing the effects in near IR spectral measurements attributable to shifts in skin temperature at a tissue measurement site. Spectroscopic monitoring of skin temperature at the measurement site provides near-instantaneous temperature readings by eliminating thermal time constants. A thermistor positioned at the measurement site provides active control. The spectrometer and the temperature control device are incorporated into a single instrument for noninvasive measurement of blood glucose concentration.

**In article** [21] the seminal Diabetes Control & Complications Trial Research Group concluded that frequent glucose monitoring is necessary to reduce the

complications of diabetes. However, all glucose monitors available require invasive techniques with the most widely used method of self-monitoring, obtaining blood from a finger prick, causing pain and discomfort which results in poor compliance.

**Lawson** [22] discovered that skin temperature over a cancer in the breast was higher than that of normal tissue. Thermal imaging (thermography) is a noninvasive diagnostic technique that allows the examiner to visualize and quantify changes in skin surface temperature.

**GlucoWatch** [23] by Cygnus, Inc. is the only minimally invasive instrument approved by FDA as an adjunctive device to supplement blood glucose testing. The device transdermally extracts interstitial fluid from the skin using iontophoresis. An extremely low electric current pulls interstitial fluid glucose through the skin. However, the GlucoWatch still requires daily calibration of the instrument using the invasive finger-stick method.

**CGMS** [24] by MiniMed Inc. is a subcutaneous, continuous blood glucose monitoring system that directly records and stores concentration values in memory. This invasive device does not provide measurements directly to the patient and is available for professional use only.

**Klonoff** [25] and **Koshinsky** [26] provide reviews on approaches for non-invasive blood glucose measurements. In recent years, infrared (IR) spectroscopy has emerged as the analytical method of choice founded on the spectrum of IR frequencies characteristic of the analyte itself instead of relying on reagents and color reactions.

**Kajiwara** [27] reported using Fourier Transformed Infrared Spectroscopy (FTIR) methods for quantitative measurements of glucose concentration in blood and serum samples at characteristic absorbance peaks.

Different approaches in infrared absorption are described in following references: **Bauer** [28], **Bhandare** [29], **Heise** [30], **Cadet** [31], **Budinova** [32], **Vonach** [33]. None of these devices are commercially available. These devices utilize absorption, transmission, and reflection methods for spectroscopically analyzing blood glucose concentration.

The analytical methods based on Thermal Emission Spectroscopy (TES) are described in book by **Willis** [34] as well as in the following references: **Chase** [35], **DeBlase** [36], **Sullivan** [37], **Keresztury** [38], **Friedrich** [39].

**Jensen** [40] shows the effects of temperature variation in near infrared (NIR) spectral measurements.

**Malchoff** [41] shows that if spectral thermal emission measurements are performed in well controlled ambient conditions as described for in vitro experiment, it is not necessary to include additional parameters in calculation of glucose concentration from intensity of glucose thermal emission spectral lines. It shows also clinical results of blood glucose measurements by measuring the infrared radiation from the subject tympanic membrane naturally emitted as heat in a manner similar to a non-contact ear tympanic thermometer. For the measurements in real life conditions, especially for in vivo and non-invasive, one must incorporate necessary environmental and physiological subject's parameters to compensate their influence on spectral measurements.

**Planck** [42] shows in his fundamental monography the correspondence between the emission and absorption spectra as he theoretically predicted. Planck describes the

difference between absorption spectroscopy and thermal emission phenomena where the entire volume of the emitting body is a source of radiation, which can be measured.

**Griffiths** in his book [43] shows one of the first thermal emission spectra of chemical interest that of aniline at 30 deg C was shown experimentally in 1965 with its transmittance spectrum for comparison.

#### REMARKS:

None of the references shows an apparatus for an infrared spectral measurements integrated with temperature and humidity sensors. The invented device integrates ambient temperature sensor, subject body temperature sensor, subject tympanic membrane temperature sensor and ambient humidity sensor. It has the objective to provide the infrared spectral monitor, which is not influenced by environmental conditions such as ambient temperature and humidity as well as by subject physiological condition such as body temperature and size and physiological state of an ear canal.


None of the references provide the spectral analyte specific infrared measurements from this same spot of tissue as non-contact temperature measurements by infrared radiation sensor.

None of the references provide the spectral analyte specific infrared measurements in continuous manner that is integrated with ambient temperature sensor, subject body temperature sensor, subject tympanic membrane temperature sensor and ambient humidity sensor.


None of the references provide the spectral analyte specific infrared measurements in continuous manner that is not influenced by environmental conditions such as ambient temperature and humidity as well as by subject physiological condition such as body temperature and size and physiological state of an ear canal.

To the contrary all the referenced and known as a prior art methods and devices are not integrated with all sensors as in invented improvements of the method and apparatus as described in specification and attached claims.

Very respectfully,



Janusz M. Buchert  
180 Cabrini Blvd., #79  
New York, NY 10033  
Tel: (212) 928 0424  
Fax: (212) 568 6214



Substitute for form 1449/PTO

**(Use as many sheets as necessary)**

Sheet

1

of

5

Application Number

10/604,851
------------

Filing Date

08/21/2003

First Named Inventor

Janusz M. Buchert

Art Unit

3737

Examiner Name

Attorney Docket Number

**Complete if Known**

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

to a collection of information unless it contains a valid OMB control number.

RECEIVED

NOV 26 2003

TECHNOLOGY CENTER R3700

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (# known)			
	1	US- 5,666,956	09-16-1997	Buchert	all
	2	US- 5,823,966	10-20-1998	Buchert	all
	3	US- 4,797,840	01-10-1989	Fraden	all
	4	US- 4,169,676	10-02-1979	Kaiser	all
	5	US- 5,115,133	05-19-1992	Knudson	all
	6	US- 5,146,091	09-08-1992	Knudson	all
	7	US- 5,179,951	01-19-1993	Knudson	all
	8	US- 5,515,847	05-14-1996	Braig et al	all
	9	US- 5,615,672	04-01-1997	Braig et al	all
	10	US- 5,900,632	05-04-1999	Sterling et al	all
	11	US- 6,025,597	02-15-2000	Sterling et al	all
	12	US- 6,049,081	04-11-2000	Sterling et al	all
	13	US- 6,072,180	06-06-2000	Kramer et al	all
	14	US- 6,161,028	12-12-2000	Braig et al	all
	15	US- 6,198,949 B1	03-06-2001	Braig et al	all
	16	US- 6,556,850 B1	04-29-2003	Braig et al	all
	17	US- 6,577,885 B1	06-10-2003	Braig et al	all
	18	US- 6,580,934 B1	06-17-2003	Braig et al	all
	19	US- 6,002,953	12-14-1999	Block	all

## FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**(Use as many sheets as necessary)**

Sheet	2	of	5
-------	---	----	---

**Complete if Known**

Application Number	10/604,851
Filing Date	08/21/2003
First Named Inventor	Janusz M. Buchert
Art Unit	3737
Examiner Name	
Attorney Docket Number	

RECEIVED

NOV 26 2003

TECHNOLOGY CENTER R3700

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS



[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Compl t if Known</b>	
		Application Number	10/604,851
		Filing Date	08/21/2003
		First Named Inventor	Janusz M. Buchert
		Art Unit	3737
Examiner Name			
Attorney Docket Number			
Sheet	3	of	5

RECEIVED

NOV 26 2003

TECHNOLOGY CENTER R3700


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	21	"The Diabetic Control and Complications Trial Research Group" New Engl. J. Med. 329:977-1036, 1993	
	22	LAWSON R: "Implication of Surface Temperature in the Diagnosis of Breast Cancer", Can. Med. Assoc. J.: 75:309-310, 1956	
	23	"GlucoWatch Automatic Glucose Biographer and Autosensor", Cygnus Inc., prescribing information, available from <a href="http://www.glucowatch.com">http://www.glucowatch.com</a>	
	24	"Medtronic/MiniMed CGMS specification", product specification, available from <a href="http://www.minimed.com">http://www.minimed.com</a>	
	25	KLONOFF D.C. "Non-invasive Blood Glucose Monitoring" Diabetes Care 20:433-437, 1997	
	26	KOSHINSKY et al. "Sensors for Glucose Monitoring: Technical and Clinical Aspects" Diabetes Metab Res Rev 17:113-123, 2001	
	27	KAJIWARA et al. "Spectroscopic Quantitative Analysis of Blood Glucose by Fourier Transform Infrared Spectroscopy with an ATR Prism" Med Prog Technol 18: 181-189, 1992	
	28	BAUER et al., "Monitoring of Glucose in Biological Fluids by FTIR Spectrometry with a Cylindrical Internal Reflectance Cell", Analytica Chimica Acta 197: 295-301, 1987	
	29	BHANDARE et al, "Glucose Determination in Simulated Plasma Blood Serum Solution by FTIR Spectroscopy" Vibrational Spectroscopy 6:363-378, 1994	
	30	HEISE et al., "Multicomponent Assay for Blood Substrates in Human Plasma by Mid-Infrared Spectroscopy and its Evaluation for Clinical Analysis", Applied Spectroscopy, 48:85-95,	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to provide information to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/604,851
Filing Date	08/21/2003
First Named Inventor	Janusz M. Buchert
Art Unit	3737
Examiner Name	
Attorney Docket Number	

**RECEIVED**

NOV 26 2003

TECHNOLOGY CENTER R3700

Sheet

4

of

5

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	31	CADET F., "Method for Classification of Biological FTIR Spectra Prior to Quantitative Analysis", Applied Spectroscopy 50: 1590-1596, 1996	
	32	BUDINOVA ET AL., "Application of Molecular Spectroscopy in the Mid-Infrared Region to the Determination of Glucose and Cholesterol in Whole Blood" Appl. Spect. 51:631-635, 1997	
	33	VONACH et al., "Application of Mid-Infrared Transmission Spectrometry to the Direct Determination of Glucose in Whole Blood", Appl. Spect. 52:820-822, 1998	
	34	WILLIS H.A. "Laboratory Methods in Vibrational Spectroscopy" New York, J. Wiley & Sons, 1987	
	35	CHASE D.B. "The Sensitivity and Limitation of Condensed Phase Infrared Emission Spectroscopy", Appl. Spect. 35:77-81, 1981	
	36	DEBLASE et al., Infrared Spectroscopy: a Theoretical and Experimental Review", Appl. Spect. 45:611-618, 1991	
	37	SULLIVAN et al., "Surface Analysis with FTIR Emission Spectroscopy", Appl. Spect. 46:811-818, 1992	
	38	KERESZTURY et al., "Quantitative Aspects of FTIR Emission Spectroscopy and Simulation of Emission-Absorption Spectra", Analytical Chemistry 67:3782-3787, 1995	
	39	FRIEDRICH et al., "Emission Spectroscopy: An Excellent Tool for the Infrared Characterization of Textile Fibers", Appl. Spect. 52:1530-1535, 1998	
	40	JENSEN et al., "Influence of Temperature and Water on Aqueous Glucose Absorption Spectra in Near- and Mid-Infrared", Appl. Spect. 57:28-36, 2003	


Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

RECEIVED

NOV 26 2003

TECHNOLOGY CENTER R3700

Sheet

5

of

5

Application Number

10/604,851

Filing Date

08/21/2003

First Named Inventor

Janusz M. Buchert

Art Unit

3737

Examiner Name

Attorney Docket Number

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	41	MALCHOFF et al., "A Novel Noninvasive Blood Glucose Monitor", Diabetes Care 25(12):2268-2275, 2002	
	42	PLANCK Max: "The Theory of Heat Radiation", New York, Dover Publication, 1991	
	43	GRIFFITHS P.R., "Chemical IR Fourier Transform Spectroscopy", New York, J. Wiley & Sons, 1975	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.